Navigation Links
Invida Selects LaVoie Group as Public Relations Agency of Record
Date:3/8/2010

LaVoie Group, a life science-focused strategic communications agency, announced today that it has been selected by Invida Group, the leading provider of healthcare brands and services in Asia Pacific, to develop and execute its corporate communications and public relations program.

Salem, MA (Vocus) February 8, 2010 -- LaVoie Group, a life science-focused strategic communications agency, announced today that it has been selected by Invida Group, the leading provider of healthcare brands and services in Asia Pacific, to develop and execute its corporate communications and public relations program. Singapore-based Invida has a presence in 13 countries in the Asia-Pacific region, and has selected LaVoie Group to build upon its corporate identity and brand awareness as the company moves into a phase of focused expansion in key growth regions such as China and India.

Donna L. LaVoie, President & CEO of LaVoie Group, commented, "Invida provides pharmaceutical and biotechnology partners proven brand and sales experience and track record in bringing their products to the three billion patients in the fastest growing region in the world – the Asia-Pacific region. We look forward to continuing our work with the Invida team to develop and execute a corporate communications program, designed to align with Invida’s business strategy and growth opportunities in these exciting markets.”

John A. Graham, Chief Executive Officer of Invida Group Pte Ltd, added, "We selected LaVoie Group for their experience working with leading life sciences corporate brands. As Invida expands throughout Asia Pacific and grows its presence in these key markets, LaVoie Group will help us in creating and executing a strong and cohesive strategy to further our message as we seek to continue working with top multi-national corporations to market and sell their product lines throughout the region.”

About Invida Group Pte Ltd.
Invida improves the lives of patients in Asia by commercializing differentiated pharmaceutical products of superior quality - the result of which will allow all our stakeholders to prosper. We do this through our proven brand marketing and sales know-how, strong expertise across a number of key therapeutic categories and deep experience in all critical Asian markets. Comprehensive functional capabilities provide rapid market access delivered by our passionate team of professionals.

With more than 4,000 employees in 13 countries in Asia Pacific, Invida operates across the commercial value chain from regulatory approval and product launch to lifecycle management. We manage a portfolio of proprietary healthcare brands, as well as licensed products from small biotech firms and large multinational companies. Partnering is a critical component of Invida’s business model. We collaborate closely with our partners in developing effective strategies and put our extensive experience behind maximizing the potential of the assets entrusted to us. For more information, please visit http://www.invida.com.

About LaVoie Group, Inc.
LaVoie Group provides senior-level counsel and tactical implementation of strategic communications programs designed to properly position, create visibility and drive value for each client. We help our life sciences companies attract capital, reach corporate partners, generate revenue and build their companies through integrated communications programs. In addition to Invida, our clients include emerging and leading global brands in the life science sector, such as Pfizer, sanofi-aventis, Vertex Pharmaceuticals, Genetix Pharmaceuticals, Rockwell Medical, Cardioxyl Pharmaceuticals, and Profectus Biosciences.

In 2009, LaVoie Group was selected for three industry awards including the coveted Impact Award for "Best Industry-Exclusive Agency," sponsored by the League of American Communications Professionals (LACP) and the Bell Ringer merit award for corporate identity by the New England Publicity Club. LaVoie Group is also ranked by O’Dwyer’s PR Report as one of the leading independent healthcare PR firms in the U.S. For more information, please visit http://www.lavoiegroup.com.

Contact:
Donna L. LaVoie
President & CEO
LaVoie Group
978-745-4200 X103
http://www.lavoiegroup.com

# # #

Read the full story at http://www.prweb.com/releases/Invida_Group/LaVoie_Group/prweb3573384.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Invida Selects LaVoie Group as Public Relations Agency of Record
2. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
3. Detroit Department of Health and Wellness Promotion Selects Netsmart Technologies Public Health Software
4. E-Rad Solutions Selects Compressus Enterprise Systems Integration Technology to Fuel Entry Into Teleradiology Market
5. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
6. GeneSeek Selects the British Midlands as Base for New UK/European Operations
7. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
8. GSA Selects Cascades Technologies, Inc. (CTi) to Support USA.gov
9. ProCure Selects IMPAC as Provider of Oncology Information Systems
10. CIGNA Medical Group Selects Allscripts for Electronic Health Record
11. Holy Cross Hospital Selects Allscripts Electronic Health Record
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Invida Selects LaVoie Group as Public Relations Agency of Record
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
Breaking Biology Technology:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
Breaking Biology News(10 mins):